Novel solutions for complex pain
At AlgoTx we develop novel solutions to relieve patients with difficult-to-treat « Complex Pain ».
We do so by prioritizing indications that have no proven and approved therapy, and tailoring treatment to the very specific needs of the affected patients.
FDA aprouved ATX01's entry into Phase 2 in Chemotherapy-Induced Peripheral Neuropathy. In parallel, we are exploring its potential in a rare and painful disease, erythromelalgia.
ATX01’s topical administration enables the direct blockade of pain messaging in the nerve fibers of the skin, and limits the systemic side-effects potential associated with oral or intravenous drugs.